{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:37:48Z","timestamp":1790793468878,"version":"4.1.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG#:5064-A-5"],"award-info":[{"award-number":["RG#:5064-A-5"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002732","name":"Christopher Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002732","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000261","name":"Multiple Sclerosis Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Don Paty Career Development Award"},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Consortium of MS Centres"},{"DOI":"10.13039\/100000890","name":"National MS Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1093\/brain\/awz055","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T23:18:03Z","timestamp":1550877483000},"page":"1324-1333","source":"Crossref","is-referenced-by-count":46,"title":["Multiple sclerosis: effect of beta interferon treatment on survival"],"prefix":"10.1093","volume":"142","author":[{"given":"Elaine","family":"Kingwell","sequence":"first","affiliation":[{"name":"Faculty of Medicine (Neurology) and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Leray","sequence":"additional","affiliation":[{"name":"EA 7449 REPERES, Ecole des Hautes Etudes en Sant\u00e9 Publique (EHESP), Rennes, Rennes Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine (Neurology) and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Petkau","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Edan","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire (CHU) de Rennes, Rennes, Rennes Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Oger","sequence":"additional","affiliation":[{"name":"Faculty of Medicine (Neurology) and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tremlett","sequence":"additional","affiliation":[{"name":"Faculty of Medicine (Neurology) and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"2019042904532642300_awz055-B29"},{"key":"2019042904532642300_awz055-B1","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/WNL.0b013e3182050388","article-title":"Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials","volume":"76","author":"Bates","year":"2011","journal-title":"Neurology"},{"issue":"Pt 4","key":"2019042904532642300_awz055-B2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/brain\/awh104","article-title":"Trends in survival and cause of death in Danish patients with multiple sclerosis","volume":"127","author":"Bronnum-Hansen","year":"2004","journal-title":"Brain"},{"key":"2019042904532642300_awz055-B3","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"N Engl J Med"},{"key":"2019042904532642300_awz055-B4","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1212\/WNL.0000000000004037","article-title":"Evaluating the safety of beta-interferons in MS: a series of nested case-control studies","volume":"88","author":"de Jong","year":"2017","journal-title":"Neurology"},{"key":"2019042904532642300_awz055-B5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"2019042904532642300_awz055-B6","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.0b013e3181c97d99","article-title":"Interferon-beta mechanisms of action in multiple sclerosis","volume":"74","author":"Dhib-Jalbut","year":"2010","journal-title":"Neurology"},{"key":"2019042904532642300_awz055-B7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-5-5","article-title":"Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure","volume":"5","author":"Essebag","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"2019042904532642300_awz055-B8","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"2019042904532642300_awz055-B9","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/pds.3667","article-title":"Association between beta-interferon exposure and hospital events in multiple sclerosis","volume":"23","author":"Evans","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2019042904532642300_awz055-B10","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1212\/WNL.0b013e318205051d","article-title":"Long-term follow-up of clinical trials of multiple sclerosis therapies","volume":"76","author":"Freedman","year":"2011","journal-title":"Neurology"},{"issue":"Pt 10","key":"2019042904532642300_awz055-B11","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1099\/0022-1317-81-10-2341","article-title":"Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures","volume":"81","author":"Goodbourn","year":"2000","journal-title":"J Gen Virol"},{"key":"2019042904532642300_awz055-B12","doi-asserted-by":"crossref","first-page":"e105207","DOI":"10.1371\/journal.pone.0105207","article-title":"Causes of death among commercially insured multiple sclerosis patients in the United States","volume":"9","author":"Goodin","year":"2014","journal-title":"PLoS One"},{"key":"2019042904532642300_awz055-B13","first-page":"2","article-title":"Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNbeta-1b study","author":"Goodin","year":"2012","journal-title":"BMJ Open"},{"key":"2019042904532642300_awz055-B14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1352458512451660","article-title":"Evidence-based medicine: promise and pitfalls","volume":"18","author":"Goodin","year":"2012","journal-title":"Mult Scler"},{"key":"2019042904532642300_awz055-B15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.0b013e3182535cf6","article-title":"Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial","volume":"78","author":"Goodin","year":"2012","journal-title":"Neurology"},{"key":"2019042904532642300_awz055-B16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/1352458512448449","article-title":"The AAN response to evidence-based medicine: promise and pitfalls","volume":"18","author":"Gronseth","year":"2012","journal-title":"Mult Scler"},{"key":"2019042904532642300_awz055-B17","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1177\/1352458508093890","article-title":"Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway","volume":"14","author":"Grytten Torkildsen","year":"2008","journal-title":"Mult Scler"},{"key":"2019042904532642300_awz055-B18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"2019042904532642300_awz055-B19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"2019042904532642300_awz055-B20","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"2019042904532642300_awz055-B21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1468-1331.2006.01147.x","article-title":"A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting","volume":"13","author":"Karussis","year":"2006","journal-title":"Eur J Neurol"},{"key":"2019042904532642300_awz055-B22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/jnnp-2011-300616","article-title":"Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada","volume":"83","author":"Kingwell","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2019042904532642300_awz055-B23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.65.1.56","article-title":"Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry","volume":"65","author":"Koch-Henriksen","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2019042904532642300_awz055-B24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/1352458507077410","article-title":"Long-term survival of patients with multiple sclerosis in West France","volume":"13","author":"Leray","year":"2007","journal-title":"Mult Scler"},{"key":"2019042904532642300_awz055-B25","doi-asserted-by":"crossref","first-page":"e0132033","DOI":"10.1371\/journal.pone.0132033","article-title":"Excess mortality in patients with multiple sclerosis starts at 20 years from clinical onset: data from a large-scale french observational study","volume":"10","author":"Leray","year":"2015","journal-title":"PLoS One"},{"key":"2019042904532642300_awz055-B26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","article-title":"Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study","volume":"88","author":"Lunde","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2019042904532642300_awz055-B27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1212\/WNL.0000000000001718","article-title":"Effect of comorbidity on mortality in multiple sclerosis","volume":"85","author":"Marrie","year":"2015","journal-title":"Neurology"},{"key":"2019042904532642300_awz055-B28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jnnp.58.4.417","article-title":"Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in More and Romsdal, Norway","volume":"58","author":"Midgard","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2019042904532642300_awz055-B30","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"2019042904532642300_awz055-B31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000359971","article-title":"Mortality and cause of death in multiple sclerosis: findings from a prospective population-based cohort in Bizkaia, Basque Country, Spain","volume":"42","author":"Rodriguez-Antiguedad Zarranz","year":"2014","journal-title":"Neuroepidemiology"},{"key":"2019042904532642300_awz055-B32","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.41.8.1193","article-title":"Cause of death in patients attending multiple sclerosis clinics","volume":"41","author":"Sadovnick","year":"1991","journal-title":"Neurology"},{"key":"2019042904532642300_awz055-B33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/CPJ.0000000000000269","article-title":"Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS","volume":"6","author":"Salter","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"2019042904532642300_awz055-B34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1212\/WNL.0b013e31829a3388","article-title":"Mortality in patients with multiple sclerosis","volume":"81","author":"Scalfari","year":"2013","journal-title":"Neurology"},{"key":"2019042904532642300_awz055-B35","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/WNL.56.11.1496","article-title":"Randomized controlled trial of interferon- beta-1a in secondary progressive MS: CLINICAL results","volume":"56","year":"2001","journal-title":"Neurology"},{"key":"2019042904532642300_awz055-B36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.msard.2016.01.007","article-title":"Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: a systematic review and meta-analysis","volume":"6","author":"Signori","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"2019042904532642300_awz055-B37","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1177\/1352458509107010","article-title":"Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients","volume":"15","author":"Smestad","year":"2009","journal-title":"Mult Scler"},{"key":"2019042904532642300_awz055-B38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nrneurol.2014.237","article-title":"Can we measure long-term treatment effects in multiple sclerosis?","volume":"11","author":"Sormani","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"2019042904532642300_awz055-B39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2019042904532642300_awz055-B40","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1177\/1352458510379244","article-title":"Causes of death among patients with multiple sclerosis","volume":"16","author":"Sumelahti","year":"2010","journal-title":"Mult Scler"},{"key":"2019042904532642300_awz055-B41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/WNL.53.4.679","article-title":"Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"2019042904532642300_awz055-B42","first-page":"CD011381","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","author":"Tramacere","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2019042904532642300_awz055-B43","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1212\/WNL.0b013e3181c1e44f","article-title":"Impact of multiple sclerosis relapses on progression diminishes with time","volume":"73","author":"Tremlett","year":"2009","journal-title":"Neurology"},{"key":"2019042904532642300_awz055-B44","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40261-013-0108-7","article-title":"Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997\u20132008","volume":"33","author":"Tsai","year":"2013","journal-title":"Clin Drug Investig"},{"key":"2019042904532642300_awz055-B45","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nrd.2017.107","article-title":"The multiple sclerosis market","volume":"16","author":"Westad","year":"2017","journal-title":"Nat Rev Drug Discov"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/142\/5\/1324\/28538139\/awz055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T04:54:42Z","timestamp":1556513682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/142\/5\/1324\/5382233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,3,18]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awz055","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735351051.793558879","asserted-by":"object"}]},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,3,18]]}}}